pharma · Breast Cancer · Prostate Cancer · UTHR
United Therapeutics Europe
United Therapeutics Europe Ltd
United Therapeutics Europe patent portfolio — 3720 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 1000 Spring Street, Silver Spring, Maryland 20910, US
- Founded
- 1996
- Employees
- 1,443
- Programs
- 1032
- Drugs
- 612
- Patents
- 3720
United Therapeutics Europe patents
3,720 pharmaceutical patents indexed for United Therapeutics Europe. 233 expire within 24 months.
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 233 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 8822540
Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation
granted -
US 8822192
Human rotavirus vaccine strains and diagnostics
granted -
US 8821866
Methods of treating and preventing colitis involving IL-13 and NK-T cells
granted -
US 8816059
Method for predicting and detecting tumor metastasis
granted -
US 8815229
Granulysin in immunotherapy
granted -
US 8809502
Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
granted -
US 8808684
Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction
granted -
US 8809400
Method to ameliorate oxidative stress and improve working memory via pterostilbene administration
granted -
US 8802835
Proteins with repetitive bacterial-Ig-like (Big) domains present in leptospira species
granted -
US 8795674
Methods and compositions for modulating immune tolerance
granted -
US 8795677
Treatment methods using an F1-V plague vaccine
granted -
US 8795680
Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-D-manno-octulsonic acid
granted -
US 8795964
GRM3 mutations and use thereof for the diagnosis and treatment of melanoma
granted -
US 8796291
A3 adenosine receptor antagonists and partial agonists
granted -
US 8796302
Methods related to the treatment of neurodegenerative and inflammatory conditions
granted -
US 8796435
Modular functional peptides for the intracellular delivery of nanoparticles
granted -
US 8790635
Live, oral vaccine for protection against Shigella dysenteriae serotype 1
granted -
US 8790639
Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin
granted -
US 8790869
Renal cell carcinoma biomarkers
granted -
US 8791074
Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
granted -
US 8785414
Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjögren's syndrome
granted -
US 8785421
Use of vitamin D in dairy mastitis treatment
granted -
US 8785609
Cloning and expression of HTLV-III DNA
granted -
US 8785601
T cell receptors and related materials and methods of use
granted -
US 8778354
Compositions and methods for modulating RSV infection and immunity
granted -
US 8778671
Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
granted -
US 8778847
Immunogenic peptides of influenza virus
granted -
US 8778889
Antimicrobial decapeptide oral hygiene treatment
granted -
US 8779001
Stat3 inhibitors
granted -
US 8779095
LAT adapter molecule for enhanced T-cell signaling and method of use
granted -
US 8772256
Codon modified immunogenic compositions and methods of use
granted -
US 8771706
Anti-RSV immunogens and methods of immunization
granted -
US 8772238
Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
granted -
US 8765802
Kinase inhibitors, compositions thereof, and methods of use therewith
granted -
US 8765146
Adenoviral vector-based malaria vaccines
granted -
US 8765141
Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host
granted -
US 8765813
Use of treprostinil to treat and prevent ischemic lesions
granted -
US 8759014
Methods of obtaining antigen-specific T cell populations
granted -
US 8754030
Defensin-antigen fusion proteins
granted -
US 8754046
MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1
granted -
US 8754081
Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling
granted -
US 8753649
Polysaccharide-protein conjugate vaccines
granted -
US 8747863
Vaccine for shigella
granted -
US 8748572
RNase a peptides, fragments and uses thereof
granted -
US 8747823
Compositions and methods for treating a keratin based substrate
granted -
US 8747859
Porcine reproductive and respiratory syndrome vaccine based on isolate JA-142
granted -
US 8748114
ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)
granted -
US 8748390
Immunogenic epitopes of NGEP antigen
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
233 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.